As per the report, the global antacids market size is predicted to be worth USD 20.53 billion by 2026 from USD 16.68 billion in 2021, growing at a CAGR of 4.24% during the forecast period.
Antacids are a group of medications that help neutralize the content of acid reflux in the stomach. It provides fast relief of heartburn, one of the main symptoms of gastroesophageal reflux digestion, and other symptoms are nausea, bloating, or belching. Antacids include magnesium carbonate, aluminum hydroxide, and magnesium trisilicate. Some people have reported allergic reactions to antacids. Antacids incorporate magnesium carbonate, aluminum hydroxide, and magnesium trisilicate. In addition, a few people have announced unfavorably susceptible responses to antacids.
MARKET DRIVERS:
The growing trend toward self-medication is increasing the demand for over-the-counter digestive products to treat gastrointestinal disorders, which is estimated to reflect the growth rate of the global antacids market.
Antacids are used to neutralize acidity and should, therefore, cause a dramatic increase in demand. However, according to a study conducted by the American Gastroenterological Association and published in the International Functional Foundation in February 2017, about one-third of the US population suffers from GERD.
The rise in the popularity of the counter drugs through digital advertisements and campaigns is lucrative to surge growth opportunities for the antacids market. The increasing prevalence to have treatment for gastrointestinal problems worldwide is creating chances for the market to grow. The geriatric population's rise propels the market's demand as acidity complications show a higher risk in aging people. The adoption of sedentary lifestyles also leads to several problems related to acidity. Growing demand for early diagnosis among individuals is also expanding the growth of the antacids market. Increasing focus on releasing quality drugs and a high production rate significantly influence the demand of the market. Rising disposable income in urban areas is leveraging the growth of the antacids market. Also, the growing priority for self-medication is elevating the growth rate of this market to the extent. Growing awareness of the early symptoms of gastrointestinal diseases is also fueling the demand for the antacids market.
MARKET RESTRAINTS:
Factors such as some side effects such as constipation, laxative effect, and allergic reactions are expected to restrain the growth rate of the global antacids market. Also, people suffering from certain medical conditions are prone to the adverse impacts that worsen their health because people with heart disease may have problems due to the high amount of sodium present in antacids.
Impact of COVID-19 on the global antacids market:
The novel coronavirus (COVID-19) pandemic has significantly impacted every business sector, including the healthcare sector. A negative impact was created by COVID 19 pandemic. People 65 Years and above are likely to deal with the acid retreat. The vagueness of the COVID 19 pandemic has made out stomachs agitates, and as of now, present proof indicates that extreme heartburn links up poor symptoms of the disease. The familiar form of heartburn medicine may surge the risk of developing COVID-19 in people. The proton-pump inhibitors are used for heartburn in people. As per the American Journal of Gastroenterology, doctors in the United States found people consuming proton-pump inhibitor (PPI) twice a day for acid reflux. Proton-pump inhibitors may threaten the gastric barrier to COVID 19 access and decrease the microbial diversity in the gut. The use of PPI is a threatening factor for testing positive with COVID 19. Patients who tested positive are observed to improve the disease outcomes with some proton-pump inhibitors. Despite the negative impact of COVID-19, the global antacids market is still expected to register a healthy growth rate during the forecast period.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Drug Class, Formulation Type, Distribution Channel, Disease Indications, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
This market research report on the global antacids market has been segmented and sub-segmented based on the drug class, formulation type, distribution channel, disease indications, end-user, and region.
Antacids Market – By Drug Class:
The Proton pump inhibitors segment led the market in 2020, and the trend is anticipated to continue in the forecast period. However, the acid neutralizer segment emerges as a significant segment because of their occasional heartburn and availability range.
Antacids Market – By Formulation Type:
Based on the formulation type, the tablet segment held the majority of the share in the global market in 2020 and is anticipated to be the highest growing segment due to convenience in administration, low pricing, and mostly availability.
Antacids Market – By Distribution Channel:
Based on the distribution channel, the online pharmacies and drug stores, and pharmacies at the hospitals are expected to occupy the majority of the market share during the forecast period. The rising adoption of e-commerce and an increase in online stores boost the market's growth.
Antacids Market – By Disease Indications:
Antacids Market – By Region:
The North American regional market held the leading share in the overall market due to the increasing number of gastro-oesophageal diseases and the growing geriatric population. Asia pacific stood second in contributing to the market share. China and India are the vital dominant regions due to improvements and healthcare services.
The antacids market in Europe is growing faster for the past few years and continues the same flow in the coming years. Germany is holding the highest share of the market when compared with other countries. Germany- Increasing capital income is a significant factor magnifying the demand of the market in this region. In addition, the rise in the consumption rate of drugs related to gastric problems increases the market's growth.
KEY MARKET PLAYERS:
Companies dominating the global antacids market are GlaxoSmithKline PLC, Abbott Laboratories, Pfizer, Inc., Sun Pharmaceuticals, and Dabur.
RECENT MARKET HAPPENINGS:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Introduction
5.1.2 Proton Pump Inhibitors
5.1.3 H2 Antagonist
5.1.4 Pro-motility agents
5.1.5 Acid Neutralizers
5.1.6 Y-o-Y Growth Analysis, By Drug Class
5.1.7 Market Attractiveness Analysis, Drug Class
5.1.8 Market Share Analysis, By Drug Class
5.2 Formulation Type
5.2.1 Introduction
5.2.2 Tablet
5.2.3 Liquid
5.2.4 Powder
5.2.5 Y-o-Y Growth Analysis, By Formulation Type
5.2.6 Market Attractiveness Analysis, By Formulation Type
5.2.7 Market Share Analysis, By Formulation Type
5.3 Distribution Channel
5.3.1 Introduction
5.3.2 Hospital Pharmacies
5.3.3 Retail pharmacies
5.3.4 Other
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
5.4 Disease Indications 5.4.1 Introduction
5.4.2 Cancer
5.4.3 CardiovascularDisorders
5.4.4 Neurological Disorders
5.4.5 Immunological Disorders
5.4.6 Other Diseases
5.4.7 Y-o-Y Growth Analysis, By Disease Indications
5.4.8 Market Attractiveness Analysis, By Disease Indications
5.4.9 Market Share Analysis, By Disease Indications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Class
6.1.3.3 By Formulation Type
6.1.3.4 By Distribution Channel
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Class
6.1.4.3 By Formulation Type
6.1.4.4 By Distribution Channel
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Class
6.1.5.3 By Formulation Type
6.1.5.4 By Distribution Channel
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Glaxo Smith
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories
8.3 Pfizer Inc
8.4 Sun Pharmaceuticals
8.5 Consumer Health
8.6 Dabur
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
Apr 2021
Apr 2021
